{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:00:35Z","timestamp":1787065235664,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.contraception.2010.07.008","type":"journal-article","created":{"date-parts":[[2010,10,8]],"date-time":"2010-10-08T04:31:41Z","timestamp":1286512301000},"page":"107-115","source":"Crossref","is-referenced-by-count":51,"title":["Vaginal ring contraception"],"prefix":"10.1016","volume":"83","author":[{"given":"Jennifer","family":"Kerns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Darney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2010.07.008_bb0005","series-title":"United Nations Department of Economic and Social Affairs","first-page":"2009","author":"World Contraceptive Use","year":"2009"},{"key":"10.1016\/j.contraception.2010.07.008_bb0010","series-title":"Adding it up: the benefits of investing in sexual and reproductive health care","author":"Singh","year":"2004"},{"key":"10.1016\/j.contraception.2010.07.008_bb0015","unstructured":"Blackburn R, Cunkelman A, Zlidar V. Oral contraceptives \u2014 an update. Popul Rep A Oral Contracept 2000;28:1\u201316, 25\u201332."},{"key":"10.1016\/j.contraception.2010.07.008_bb0020","series-title":"Contraceptive technology","author":"Hatcher","year":"2004"},{"key":"10.1016\/j.contraception.2010.07.008_bb0025","first-page":"355","article-title":"Unintended pregnancies and use, misuse and discontinuation of oral contraceptives","volume":"40","author":"Rosenberg","year":"1995","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2010.07.008_bb0030","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0029-7844(00)01029-2","article-title":"Triphasic norgestimate\u2013ethinyl estradiol for treating dysfunctional uterine bleeding","volume":"96","author":"Davis","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0010-7824(92)90095-B","article-title":"The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status","volume":"46","author":"Larsson","year":"1992","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0010-7824(90)90078-A","article-title":"The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea","volume":"42","author":"Milsom","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0045","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00003081-198109000-00014","article-title":"Oral contraception: mechanism of action","volume":"24","author":"Bronson","year":"1981","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0050","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/bjc.1995.260","article-title":"Endometrial and ovarian cancer and oral contraceptives\u2014findings in a large cohort study","volume":"71","author":"Vessey","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.contraception.2010.07.008_bb0055","first-page":"95","article-title":"Patient adherence with the contraceptive patch dosing schedule versus oral contraceptives","volume":"60S","author":"Creasy","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0029-7844(02)02124-5","article-title":"Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring","volume":"100","author":"Dieben","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2010.07.008_bb0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0002-9378(16)33897-2","article-title":"Contraception by means of a Silastic vaginal ring impregnated with medroxy progesterone acetate","volume":"107","author":"Mishell","year":"1970","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0080","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.ajog.2004.01.056","article-title":"New delivery systems in contraception: vaginal rings","volume":"190","author":"Johansson","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0010-7824(81)90007-X","article-title":"Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring: I. Carbohydrate metabolism and liver function","volume":"24","author":"Ahren","year":"1981","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/humrep\/16.3.469","article-title":"Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol","volume":"16","author":"Roumen","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2010.07.008_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.fertnstert.2005.06.040","article-title":"Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of the contraceptive vaginal ring and an oral contraceptive","volume":"85","author":"Roumen","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.07.008_bb0100","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1080\/13625187.2002.11949330","article-title":"Complete and robust ovulation inhibition with NuvaRing","volume":"7","author":"Killick","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.07.008_bb0105","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/humrep\/deh493","article-title":"Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study","volume":"19","author":"Duijkers","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2010.07.008_bb0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0015-0282(01)01689-2","article-title":"Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition","volume":"75","author":"Mulders","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.07.008_bb0115","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1093\/humrep\/17.10.2594","article-title":"Ovarian function with a novel combined contraceptive vaginal ring","volume":"17","author":"Mulders","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2010.07.008_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.contraception.2004.03.009","article-title":"Contraceptive failure in the United States","volume":"70","author":"Trussell","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2006.07.004","article-title":"Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 mcg of ethinyl estradiol and 3 mg of drospirenone","volume":"74","author":"Ahrendt","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.contraception.2004.09.001","article-title":"Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial","volume":"71","author":"Oddsson","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0135","first-page":"CD003552","article-title":"Skin patch and vaginal ring versus oral contraceptives for contraception","volume":"3","author":"Lopez","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2010.07.008_bb0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/13625180701440180","article-title":"Clinical experience with NuvaRing in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages","volume":"12","author":"Merki-Feld","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.07.008_bb0145","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.contraception.2005.11.003","article-title":"Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive","volume":"73","author":"Schafer","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0150","first-page":"267","article-title":"Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial","volume":"111","author":"Creinin","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13625180500389547","article-title":"The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands","volume":"11","author":"Roumen","year":"2006","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.07.008_bb0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2006.03.022","article-title":"Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives","volume":"74","author":"Sabatini","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0165","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/AOG.0b013e3181cf45dc","article-title":"Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial","volume":"115","author":"Gilliam","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0170","first-page":"CD003989","article-title":"20 \u03bcg versus >20 \u03bcg estrogen combined oral contraceptives for contraception","volume":"1","author":"Gallo","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2010.07.008_bb0175","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/01.AOG.0000136082.59644.13","article-title":"A comparison between the vaginal ring and oral contraceptives","volume":"104","author":"Veres","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0180","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1067\/mob.2002.121103","article-title":"Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel\/ethinyl estradiol","volume":"186","author":"Bjarnadottir","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0185","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.fertnstert.2009.01.071","article-title":"Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis","volume":"93","author":"Verecellini","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.07.008_bb0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.AOG.0000164483.13326.59","article-title":"Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive","volume":"106","author":"Westhoff","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0195","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/humrep\/deh604","article-title":"Superior cycle control with a contraceptive vaginal ring mcg ethinylestradiol and 150 compared with an oral contraceptive containing 30 mcg levonorgestrel: a randomized trial","volume":"20","author":"Oddsson","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2010.07.008_bb0200","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/humrep\/del162","article-title":"Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 \u03bcg ethinyl estradiol and 3 mg drospirenone","volume":"21","author":"Milsom","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2010.07.008_bb0205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.contraception.2005.05.008","article-title":"Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive","volume":"72","author":"O'Connell","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0210","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/humrep\/deh686","article-title":"Effects of two types of hormonal contraception\u2014oral versus intravaginal\u2014on the sexual life of women and their partners","volume":"20","author":"Guida","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2010.07.008_bb0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0010-7824(03)00025-8","article-title":"Effects of a low-dose and ultra-low-dose combine oral contraceptive on bone turnover and bone mineral density in young, fertile women: a prospective controlled randomized study","volume":"67","author":"Nappi","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.contraception.2009.09.011","article-title":"Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study","volume":"81","author":"Massaro","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.contraception.2005.08.002","article-title":"Medical eligibility criteria for new contraceptive methods: combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant","volume":"73","author":"Gaffield","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0010-7824(03)00073-8","article-title":"Oral contraceptive use and the risk of myocardial infarction: a meta-analysis","volume":"68","author":"Khader","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0002-9378(99)70182-1","article-title":"Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States","volume":"180","author":"Schwingl","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0240","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(08)60694-7","article-title":"Stroke","volume":"371","author":"Donnan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2010.07.008_bb0245","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/bmj.b3914","article-title":"Migraine and cardiovascular disease: systematic review and meta-analysis","volume":"339","author":"Schurks","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2010.07.008_bb0250","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(96)90669-8","article-title":"History of migraine and risk of cerebral ischaemia in young adults","volume":"347","author":"Carolei","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2010.07.008_bb0255","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0029-7844(02)01984-1","article-title":"Contraception for women in selected circumstances","volume":"99","author":"Curtis","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0260","first-page":"55","article-title":"in conjunction with the clinical and scientific committee of the faculty of family planning and reproductive health care and the family planning association. Combined oral contraceptives, migraine and ischaemic stroke","volume":"24","author":"MacGregor","year":"1998","journal-title":"Br J Fam Plan"},{"key":"10.1016\/j.contraception.2010.07.008_bb0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.318.7175.13","article-title":"Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"318","author":"Chang","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2010.07.008_bb0270","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0010-7824(98)00019-5","article-title":"Hormonal contraception and risk of cardiovascular disease","volume":"57","author":"Farley","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2010.07.008_bb0280","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2010.07.008_bb0285","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.thromres.2008.04.022","article-title":"Effects of the contraceptive patch, the vaginal ring, and an oral contraceptive on APC resistance and SHBG: a cross-over study","volume":"123","author":"Fleischer","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2010.07.008_bb0290","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2008.07.004","article-title":"Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis","volume":"78","author":"Jensen","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.contraception.2009.05.131","article-title":"Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis","volume":"81","author":"van Vliet","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0300","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.AOG.0000175144.08035.74","article-title":"Extended regimens of the contraceptive vaginal ring","volume":"106","author":"Miller","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0305","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.contraception.2009.10.007","article-title":"Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects","volume":"81","author":"Barreiros","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0310","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.contraception.2009.05.004","article-title":"Extended regimens of the contraceptive vaginal ring: cycle control","volume":"80","author":"Guazzelli","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/AOG.0b013e3181842071","article-title":"Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring","volume":"112","author":"Sulak","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0320","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2265.1999.00701.x","article-title":"The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen\u2013progestogen treatment","volume":"50","author":"Pasquali","year":"1999","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0325","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jcem-38-5-727","article-title":"Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive","volume":"38","author":"Givens","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2010.07.008_bb0330","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/00016348509155112","article-title":"Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome","volume":"64","author":"Cullberg","year":"1985","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2010.07.008_bb0335","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1469-0705.1998.12030180.x","article-title":"Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome","volume":"12","author":"Battaglia","year":"1998","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.07.008_bb0340","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.fertnstert.2009.05.044","article-title":"Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized pilot study","volume":"94","author":"Battaglia","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.07.008_bb0345","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.contraception.2009.01.012","article-title":"Route of administration of contraceptives containing desogestrel\/etonogestrel and insulin sensitivity: a prospective randomized study","volume":"80","author":"Cagnacci","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0350","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1542\/pir.29-11-386","article-title":"Hormonal contraception for the adolescent","volume":"29","author":"Gupta","year":"2008","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.contraception.2010.07.008_bb0355","doi-asserted-by":"crossref","unstructured":"Piccinino L, Mosher W. Trends in contraceptive use in the United States: 1982\u20131995. Fam Plan Persp 1998;30:4\u201310, 46.","DOI":"10.2307\/2991517"},{"key":"10.1016\/j.contraception.2010.07.008_bb0360","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.contraception.2004.08.010","article-title":"Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial","volume":"71","author":"Sivin","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0365","series-title":"Newer pharmacological agents, devices and delivery systems. Contraception","first-page":"101","article-title":"Transdermal contraceptive systems: innovative technology for the twenty-first century","author":"Croxatto","year":"1992"},{"key":"10.1016\/j.contraception.2010.07.008_bb0370","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0010-7824(00)00092-5","article-title":"Ovarian function during use of Nestorone\u00ae subdermal implants","volume":"61","author":"Brache","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0010-7824(99)00057-8","article-title":"Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women","volume":"60","author":"Massai","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.07.008_bb0380","series-title":"Progesterone-only vaginal ring: a technical brief","author":"Caucus on New and Underused Reproductive Technologies","year":"2009"},{"key":"10.1016\/j.contraception.2010.07.008_bb0385","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/jac\/dki326","article-title":"Long-term controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings","volume":"56","author":"Malcolm","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.contraception.2010.07.008_bb0390","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.06.026","article-title":"Intravaginal ring delivery of the reverse transcriptase inhibitor TMC120 as an HIV microbicide","volume":"325","author":"Woolfson","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.contraception.2010.07.008_bb0395","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/QAD.0b013e32832af57c","article-title":"Sustained release of microbicides by newly engineered vaginal rings","volume":"15","author":"Saxena","year":"2009","journal-title":"AIDS"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410004063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410004063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T06:02:44Z","timestamp":1559714564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782410004063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0010782410004063"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2010.07.008","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}